Immunohistochemical and Biochemical Studies with Region-specific Antibodies to Chromogranins A and B and Secretogranins II and III in Neuroendocrine Tumors

Overview

Journal Cell Mol Neurobiol

Publisher Springer

Specialties Cell Biology
Molecular Biology
Neurology

Date 2010 Nov 4

PMID 21046454

Citations 6

Authors

Guida M Portela-Gomes

Lars Grimelius

Mats Stridsberg

Affiliations

Soon will be listed here.

Abstract

This short review deals with our investigations in neuroendocrine tumors (NETs) with antibodies against defined epitopes of chromogranins (Cgs) A and B and secretogranins (Sgs) II and III. The immunohistochemical expression of different epitopes of the granin family of proteins varies in NE cells in normal human endocrine and non-endocrine organs and in NETs, suggesting post-translational processing. In most NETs one or more epitopes of the granins were lacking, but variations in the expression pattern occurred both in benign and malignant NETs. A few epitopes displayed patterns that may be valuable in differentiating between benign and malignant NET types, e.g., well-differentiated NET types expressed more CgA epitopes than the poorly differentiated ones and C-terminal secretoneurin visualized a cell type related to malignancy in pheochromocytomas. Plasma concentrations of different epitopes of CgA and CgB varied. In patients suffering from carcinoid tumors or endocrine pancreatic tumors the highest concentrations were found with epitopes from the mid-portion of CgA. For CgB the highest plasma concentrations were recorded for the epitope 439-451. Measurements of SgII showed that patients with endocrine pancreatic tumors had higher concentrations than patients with carcinoid tumors or pheochromocytomas. SgIII was not detectable in patients with NETs.

Citing Articles

Dominant Expression of Chromogranin B in Pituitary Corticotrophs and Its Putative Role in Interaction With Secretogranin III.

Kikuchi S, Odashima K, Yasui T, Torii S, Hosaka M, Gomi H J Histochem Cytochem. 2025; 73(1-2):29-53.

PMID: 39791490 PMC: 11719422. DOI: 10.1369/00221554241311965.

Differential Expression of Secretogranins II and III in Canine Adrenal Chromaffin Cells and Pheochromocytomas.

Gomi H, Nagumo T, Asano K, Konosu M, Yasui T, Torii S J Histochem Cytochem. 2022; 70(5):335-356.

PMID: 35400231 PMC: 9058372. DOI: 10.1369/00221554221091000.

Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.

Corsello A, Di Filippo L, Massironi S, Sileo F, Dolcetta Capuzzo A, Gemma M PLoS One. 2018; 13(5):e0196858.

PMID: 29723285 PMC: 5933774. DOI: 10.1371/journal.pone.0196858.

Evaluation of a new immunoassay for chromogranin A measurement on the Kryptor system.

van der Knaap R, Kwekkeboom D, Ramakers C, de Rijke Y Pract Lab Med. 2017; 1:5-11.

PMID: 28932793 PMC: 5597707. DOI: 10.1016/j.plabm.2015.03.002.

Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.

Miki M, Ito T, Hijioka M, Lee L, Yasunaga K, Ueda K Jpn J Clin Oncol. 2017; 47(6):520-528.

PMID: 28334992 PMC: 6283109. DOI: 10.1093/jjco/hyx032.

References

Portela-Gomes G, Stridsberg M, Grimelius L, Falkmer U, Falkmer S . Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodies. APMIS. 2004; 112(10):663-73. DOI: 10.1111/j.1600-0463.2004.t01-1-apm1121003.x. View

Portela-Gomes G . Chromogranin A immunoreactivity in neuroendocrine cells in the human gastrointestinal tract and pancreas. Adv Exp Med Biol. 2001; 482:193-203. DOI: 10.1007/0-306-46837-9_15. View

Grimelius L, Johansson H, Wilander E, Stridsberg M . Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. Am J Surg Pathol. 2001; 25(10):1261-7. DOI: 10.1097/00000478-200110000-00006. View

Helle K . Some chemical and physical properties of the soluble protein fraction of bovine adrenal chromaffin granules. Mol Pharmacol. 1966; 2(4):298-310. View

Banks P, Helle K . The release of protein from the stimulated adrenal medulla. Biochem J. 1965; 97(3):40C-41C. PMC: 1264782. DOI: 10.1042/bj0970040c. View

Watkinson A, Jonsson A, Davison M, Young J, Lee C, Moore S . Heterogeneity of chromogranin A-derived peptides in bovine gut, pancreas and adrenal medulla. Biochem J. 1991; 276 ( Pt 2):471-9. PMC: 1151115. DOI: 10.1042/bj2760471. View

Portela-Gomes G, Grimelius L, Stridsberg M, Bresaola E, Viale G, Pelosi G . Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung. Virchows Arch. 2005; 446(6):604-12. DOI: 10.1007/s00428-005-1222-6. View

Bordi C, Yu J, Baggi M, Davoli C, Pilato F, Baruzzi G . Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer. 1991; 67(3):663-72. DOI: 10.1002/1097-0142(19910201)67:3<663::aid-cncr2820670323>3.0.co;2-l. View

Guillemot J, Anouar Y, Montero-Hadjadje M, Grouzmann E, Grumolato L, Roshmaninho-Salgado J . Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma. Int J Cancer. 2005; 118(8):2003-12. DOI: 10.1002/ijc.21571. View

10.

Portela-Gomes G, Stridsberg M, Johansson H, Grimelius L . Complex co-localization of chromogranins and neurohormones in the human gastrointestinal tract. J Histochem Cytochem. 1997; 45(6):815-22. DOI: 10.1177/002215549704500606. View

11.

Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G . Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995; 144(1):49-59. DOI: 10.1677/joe.0.1440049. View

12.

Kruger P, Mahata S, Helle K . Catestatin (CgA344-364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul Pept. 2003; 114(1):29-35. DOI: 10.1016/s0167-0115(03)00069-7. View

13.

Ottiger H, Battenberg E, Tsou A, Bloom F, Sutcliffe J . 1B1075: a brain- and pituitary-specific mRNA that encodes a novel chromogranin/secretogranin-like component of intracellular vesicles. J Neurosci. 1990; 10(9):3135-47. PMC: 6570232. View

14.

Stridsberg M, Eriksson B, Oberg K, Janson E . A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept. 2004; 117(3):219-27. DOI: 10.1016/j.regpep.2003.10.023. View

15.

Cunningham R, Pogue K, Curry W, Johnston C, Sloan J, Buchanan K . Immunostaining for vasostatin I distinguishes between ileal and lung carcinoids. J Pathol. 1999; 187(3):321-5. DOI: 10.1002/(SICI)1096-9896(199902)187:3<321::AID-PATH258>3.0.CO;2-9. View

16.

Stridsberg M . Measurements of chromogranins and chromogranin-related peptides by immunological methods. Adv Exp Med Biol. 2001; 482:319-27. DOI: 10.1007/0-306-46837-9_25. View

17.

Hsi K, Seidah N, De Serres G, Chretien M . Isolation and NH2-terminal sequence of a novel porcine anterior pituitary polypeptide. Homology to proinsulin, secretin and Rous sarcoma virus transforming protein TVFV60. FEBS Lett. 1982; 147(2):261-6. DOI: 10.1016/0014-5793(82)81055-7. View

18.

Portela-Gomes G, Lukinius A, Grimelius L . Synaptic vesicle protein 2, A new neuroendocrine cell marker. Am J Pathol. 2000; 157(4):1299-309. PMC: 1850151. DOI: 10.1016/S0002-9440(10)64645-7. View

19.

Weiler R, Fischer-Colbrie R, Schmid K, Feichtinger H, Bussolati G, Grimelius L . Immunological studies on the occurrence and properties of chromogranin A and B and secretogranin II in endocrine tumors. Am J Surg Pathol. 1988; 12(11):877-84. DOI: 10.1097/00000478-198811000-00008. View

20.

Stridsberg M, Eriksson B, Oberg K, Janson E . A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B. Regul Pept. 2004; 125(1-3):193-9. DOI: 10.1016/j.regpep.2004.08.027. View